Autolus Therapeutics plc (AUTL) Financial Statements
Autolus Therapeutics plc (AUTL) reported trailing twelve-month revenue of $117.4M (up 292.2% year on year) and net income of -$280.2M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$232.7M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AUTLAutolus Therapeutics plcFollow AUTL — free
—
Price chart with a free account
- Market cap
- 409.9M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Sep 18 | FY2019 Dec 19 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 1.4 | 2.9 | 1.7 | 10.1 | 75.4 | 117.4 | |
| Gross profit | — | — | — | -1.3 | -21.0 | — | |
| Research & development | 36.2 | 105.4 | 130.5 | 138.4 | 117.7 | 112.6 | |
| Operating income | — | -146.1 | -179.7 | -241.4 | -270.5 | -247.4 | |
| Pre-tax income | -52.0 | -139.0 | -208.4 | -219.1 | -285.6 | -279.5 | |
| Income tax | -7.3 | -15.2 | -0.0 | 1.5 | 2.0 | 0.7 | |
| Net income | -44.8 | -123.8 | -208.4 | -220.7 | -287.5 | -280.2 | |
| Diluted EPS ($) | -1.42 | -2.88 | -1.20 | -0.86 | -1.08 | -1.06 | |
| Diluted shares (mn) | — | — | 173.9 | 255.2 | 266.1 | — |
USD millions · SEC XBRL
Autolus Therapeutics plc — questions
- What is Autolus Therapeutics plc's revenue?
- $117.4M over the twelve months to 2026-06-30, up 292.2% year on year, from its 10-Q and 10-K filings.
- What is Autolus Therapeutics plc's net income?
- -$280.2M over the twelve months to 2026-06-30.
- What is Autolus Therapeutics plc's free cash flow?
- -$232.7M over the twelve months to 2026-06-30.
- What are Autolus Therapeutics plc's diluted earnings per share?
- $-1.06 over the twelve months to 2026-06-30.
Every figure on this page comes from Autolus Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.